Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis

Jiang Jian, Yanli Pang, H Hannah Yan, Yongfen Min, Bhagelu R Achyut, M Christine Hollander, P Charles Lin, Xinhua Liang, Li Yang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Bone marrow-derived myeloid cells can form a premetastatic niche and provide a tumor-promoting microenvironment. However, subsets of myeloid cells have also been reported to have anti-tumor properties. It is not clear whether there is a transition between anti- and pro- tumor function of these myeloid cells, and if so, what are the underlying molecular mechanisms. Here we report platelet factor 4 (PF4), or CXCL4, but not the other family members CXCL9, 10, and 11, was produced at higher levels in the normal lung and early stage premetastatic lungs but decreased in later stage lungs. PF4 was mostly produced by Ly6G+CD11b+ myeloid cell subset. Although the number of Ly6G+CD11b+ cells was increased in the premetastatic lungs, the expression level of PF4 in these cells was decreased during the metastatic progression. Deletion of PF4 (PF4 knockout or KO mice) led an increased metastasis suggesting an inhibitory function of PF4. There were two underlying mechanisms: decreased blood vessel integrity in the premetastatic lungs and increased production of hematopoietic stem/progenitor cells (HSCs) and myeloid derived suppressor cells (MDSCs) in tumor-bearing PF4 KO mice. In cancer patients, PF4 expression levels were negatively correlated with tumor stage and positively correlated with patient survival. Our studies suggest that PF4 is a critical anti-tumor factor in the premetastatic site. Our finding of PF4 function in the tumor host provides new insight to the mechanistic understanding of tumor metastasis.

Original languageEnglish (US)
JournalOncotarget
DOIs
StatePublished - May 19 2016
Externally publishedYes

Fingerprint

Platelet Factor 4
Myeloid Cells
Neoplasm Metastasis
Lung
Neoplasms
Hematopoietic Stem Cells
Tumor Microenvironment
Blood Vessels
Bone Marrow

Cite this

Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis. / Jian, Jiang; Pang, Yanli; Yan, H Hannah; Min, Yongfen; Achyut, Bhagelu R; Hollander, M Christine; Lin, P Charles; Liang, Xinhua; Yang, Li.

In: Oncotarget, 19.05.2016.

Research output: Contribution to journalArticle

Jian, Jiang ; Pang, Yanli ; Yan, H Hannah ; Min, Yongfen ; Achyut, Bhagelu R ; Hollander, M Christine ; Lin, P Charles ; Liang, Xinhua ; Yang, Li. / Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis. In: Oncotarget. 2016.
@article{5ecc6ea058314ec48c98325394f2f28f,
title = "Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis",
abstract = "Bone marrow-derived myeloid cells can form a premetastatic niche and provide a tumor-promoting microenvironment. However, subsets of myeloid cells have also been reported to have anti-tumor properties. It is not clear whether there is a transition between anti- and pro- tumor function of these myeloid cells, and if so, what are the underlying molecular mechanisms. Here we report platelet factor 4 (PF4), or CXCL4, but not the other family members CXCL9, 10, and 11, was produced at higher levels in the normal lung and early stage premetastatic lungs but decreased in later stage lungs. PF4 was mostly produced by Ly6G+CD11b+ myeloid cell subset. Although the number of Ly6G+CD11b+ cells was increased in the premetastatic lungs, the expression level of PF4 in these cells was decreased during the metastatic progression. Deletion of PF4 (PF4 knockout or KO mice) led an increased metastasis suggesting an inhibitory function of PF4. There were two underlying mechanisms: decreased blood vessel integrity in the premetastatic lungs and increased production of hematopoietic stem/progenitor cells (HSCs) and myeloid derived suppressor cells (MDSCs) in tumor-bearing PF4 KO mice. In cancer patients, PF4 expression levels were negatively correlated with tumor stage and positively correlated with patient survival. Our studies suggest that PF4 is a critical anti-tumor factor in the premetastatic site. Our finding of PF4 function in the tumor host provides new insight to the mechanistic understanding of tumor metastasis.",
author = "Jiang Jian and Yanli Pang and Yan, {H Hannah} and Yongfen Min and Achyut, {Bhagelu R} and Hollander, {M Christine} and Lin, {P Charles} and Xinhua Liang and Li Yang",
year = "2016",
month = "5",
day = "19",
doi = "10.18632/oncotarget.9486",
language = "English (US)",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",

}

TY - JOUR

T1 - Platelet factor 4 is produced by subsets of myeloid cells in premetastatic lung and inhibits tumor metastasis

AU - Jian, Jiang

AU - Pang, Yanli

AU - Yan, H Hannah

AU - Min, Yongfen

AU - Achyut, Bhagelu R

AU - Hollander, M Christine

AU - Lin, P Charles

AU - Liang, Xinhua

AU - Yang, Li

PY - 2016/5/19

Y1 - 2016/5/19

N2 - Bone marrow-derived myeloid cells can form a premetastatic niche and provide a tumor-promoting microenvironment. However, subsets of myeloid cells have also been reported to have anti-tumor properties. It is not clear whether there is a transition between anti- and pro- tumor function of these myeloid cells, and if so, what are the underlying molecular mechanisms. Here we report platelet factor 4 (PF4), or CXCL4, but not the other family members CXCL9, 10, and 11, was produced at higher levels in the normal lung and early stage premetastatic lungs but decreased in later stage lungs. PF4 was mostly produced by Ly6G+CD11b+ myeloid cell subset. Although the number of Ly6G+CD11b+ cells was increased in the premetastatic lungs, the expression level of PF4 in these cells was decreased during the metastatic progression. Deletion of PF4 (PF4 knockout or KO mice) led an increased metastasis suggesting an inhibitory function of PF4. There were two underlying mechanisms: decreased blood vessel integrity in the premetastatic lungs and increased production of hematopoietic stem/progenitor cells (HSCs) and myeloid derived suppressor cells (MDSCs) in tumor-bearing PF4 KO mice. In cancer patients, PF4 expression levels were negatively correlated with tumor stage and positively correlated with patient survival. Our studies suggest that PF4 is a critical anti-tumor factor in the premetastatic site. Our finding of PF4 function in the tumor host provides new insight to the mechanistic understanding of tumor metastasis.

AB - Bone marrow-derived myeloid cells can form a premetastatic niche and provide a tumor-promoting microenvironment. However, subsets of myeloid cells have also been reported to have anti-tumor properties. It is not clear whether there is a transition between anti- and pro- tumor function of these myeloid cells, and if so, what are the underlying molecular mechanisms. Here we report platelet factor 4 (PF4), or CXCL4, but not the other family members CXCL9, 10, and 11, was produced at higher levels in the normal lung and early stage premetastatic lungs but decreased in later stage lungs. PF4 was mostly produced by Ly6G+CD11b+ myeloid cell subset. Although the number of Ly6G+CD11b+ cells was increased in the premetastatic lungs, the expression level of PF4 in these cells was decreased during the metastatic progression. Deletion of PF4 (PF4 knockout or KO mice) led an increased metastasis suggesting an inhibitory function of PF4. There were two underlying mechanisms: decreased blood vessel integrity in the premetastatic lungs and increased production of hematopoietic stem/progenitor cells (HSCs) and myeloid derived suppressor cells (MDSCs) in tumor-bearing PF4 KO mice. In cancer patients, PF4 expression levels were negatively correlated with tumor stage and positively correlated with patient survival. Our studies suggest that PF4 is a critical anti-tumor factor in the premetastatic site. Our finding of PF4 function in the tumor host provides new insight to the mechanistic understanding of tumor metastasis.

U2 - 10.18632/oncotarget.9486

DO - 10.18632/oncotarget.9486

M3 - Article

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -